Neuropace, Inc. NPCE Weighted Average Exercise Price of Vested and Expected to Vest Options
Weighted Average Exercise Price of Vested and Expected to Vest Options at other companies
Other financials
Where this comes from
Reported directly by Neuropace, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice.
The official record: Neuropace, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neuropace, Inc.'s weighted average exercise price of vested and expected to vest options.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neuropace, Inc.'s weighted average exercise price of vested and expected to vest options?
- Neuropace, Inc. (NPCE) reported weighted average exercise price of vested and expected to vest options of $7.20 in Q1 2026.
- How has Neuropace, Inc.'s weighted average exercise price of vested and expected to vest options changed year-over-year?
- Neuropace, Inc.'s weighted average exercise price of vested and expected to vest options increased by 10.1% year-over-year, from $6.54 to $7.20.
- What is the long-term trend for Neuropace, Inc.'s weighted average exercise price of vested and expected to vest options?
- Over 4 years (2021 to 2025), Neuropace, Inc.'s weighted average exercise price of vested and expected to vest options has grown at a 28.4% compound annual growth rate (CAGR), from $2.61 to $7.09.
- What does weighted average exercise price of vested and expected to vest options mean?
- This represents the average price at which holders of vested and expected-to-vest options can purchase company shares. It provides insight into the alignment between employee incentives and shareholder value creation. A lower exercise price relative to the current market price indicates a higher likelihood of option exercise and potential dilution.